TABLE 4.

50% tidal volume expiratory flow analysis.

Group	Week0	Week4	Week8	Week12	Week16	Week20
Control	1.53 ± 0.14	1.59 ± 0.10	1.63 ± 0.10	1.69 ± 0.07	1.71 ± 0.06	1.76 ± 0.08
COPD	1.55 ± 0.12	1.50 ± 0.10	1.33 ± 0.11*	1.32 ± 0.07**	1.29 ± 0.08**	1.27 ± 0.08**
BJF	1.54 ± 0.08	1.51 ± 0.15	1.33 ± 0.10	1.42 ± 0.05##	1.45 ± 0.07##	1.46 ± 0.06##
AICAR	1.53 ± 0.08	1.44 ± 0.11	1.34 ± 0.07	1.29 ± 0.04ΔΔ	1.23 ± 0.10ΔΔ	1.30 ± 0.05ΔΔ
BJF + AICAR	1.57 ± 0.12	1.48 ± 0.14	1.35 ± 0.06	1.44 ± 0.04##▲▲	1.46 ± 0.06##▲▲	1.48 ± 0.07##▲▲
APL	1.55 ± 0.12	1.45 ± 0.12	1.37 ± 0.07	1.41 ± 0.06##▲▲	1.42 ± 0.10##▲▲	1.44 ± 0.10##▲▲

Data are presented as mean ± SD (n = 6 per group). ^∗∗ P < 0.01, ^∗ P < 0.05 vs. control group;^## P < 0.01, ^# P < 0.05 vs. model group; ^ΔΔ P < 0.01, ^Δ P < 0.05 vs. BJF group; ^▲▲ P < 0.01, ^▲ P < 0.05 vs. 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) group; and ^□□ P < 0.01, ^□ P < 0.05 vs. BJF + AICAR group. APL, aminophylline.